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Poster Session II 1275,10-methylenetetrahydrofolate reductase (MTHFR) is a central
regulatory enzyme in folate metabolism. A common functional
polymorphism of the MTHFR gene occurs at C677T. The
677TT genotype produces an enzyme with only 30% of the activity
of the wild-type (677CC) enzyme. TheMTHFR polymorphism has
been shown to affect the sensitivity of patients to folate-based drugs
such as methotrexate (MTX) that is used for GVHD prophylaxis
following allogeneic hematopoietic stem cell transplantation
(HSCT). To assess the significance of C677T genotypes in
HSCT using MTX as a GVHD prophylaxis, we analyzed DNA
from159 patients with a hematological disease and theirHLA-iden-
tical sibling donors using PCR-RFLP method. The frequencies of
CC, CT and TT genotypes in the patients were 35%, 52% and
13%, respectively, and in the donors were 30%, 62% and 8%, re-
spectively. There was no significant difference in the distribution
patterns of the C677T genotypes between patients and donors (P
5 0.19). Multivariate analysis revealed a significantly lower inci-
dence of grade I-IV acute GVHD in patients with the 677TT geno-
type (relative risk, 0.35; 95% confidence interval, 0.13–0.95; P 5
0.040) and a non-malignant disease (0.22; 0.05–0.89; 0.034). There
was a significant association between a lower incidence of grade II-
IV acute GVHD and the use of bone marrow for transplantation
(0.32; 0.11–0.91; 0.032). There was no association between the in-
cidence of acute GVHD and the donor C677T genotypes. We an-
alyzed the incidence of acute GVHD in relation to the MTHFR
genotype using the Kaplan-Meier method. The incidence of grade
I-IV acute GVHD in the patients with 677TT genotype was signif-
icantly lower than in those with 677CC/CT genotype (19% versus
45%, P 5 0.035). There was a trend for a lower incidence of grade
II-IV acute GVHD in patients with 677TT genotype compared
with 677CC/CT genotype (5% versus 24%, P 5 0.077). The
C677T genotypes in the patient or donor were not associated
with the treatment-related mortality, relapse rate, relapse-free sur-
vival and overall survival. These results suggest that greater immu-
nosuppression by MTX due to low MTHFR enzyme activity
decreases the risk of acute GVHD in recipients of allogeneic
HSCT. Further studies are needed to confirm that the MTHFR
C677T polymorphism can predict the outcome of HSCT using
prophylactic MTX to prevent GVHD.346
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BAFF, a non-redundant cytokine produced by myeloid cells,
plays a critical role in the normal homeostatic maintenance, activa-
tion and function of B cells. Elevated circulating levels of BAFF,
however, have been observed in systemic autoimmune disorders
and, in murine models, have been linked to a failure to delete
auto-reactive B cells. We similarly observed elevated plasma
BAFF levels in 77 patients in an ongoingNCICGVHDnatural his-
tory protocol, with a median of 2845 pg/ml (range 92 to 17058), as
compared to 556 pg/ml (range 75 to 1834) in 18 normal donors.
Furthermore, in a subset of 22 patients in which severity of
CGVHD could be assessed by the presence of marked erythema
or sclerosis on 10 to 90% of their body surface areas (BSA), the
BAFF level correlated with the percentage of affected BSA (Spear-
man r51.63). We then explored the factors that might contribute
to elevated BAFF levels. In recipients recovering from either autol-
ogous or allogeneic transplant (without GVHD) we observed the
highest BAFF levels at day 0 (median of 10534 and 12240 pg/ml re-
spectively), when B cells were severely depleted. As B cell popula-
tions recovered to normal levels post transplant, plasma BAFF
concentrations declined (Spearman r 5 -.80 and r 5 -.60, respec-
tively), consistent with homeostatic cytokine-consumption dynam-
ics. Despite comparably high levels of BAFF (median of 11342 pg/
ml) at transplant day 0 in 16 patients who later developed CGHVD,
BAFF levels in the cross-sectional, natural history patient popula-
tion were only moderately correlated with the degree of post trans-
plant B cell recovery (r 5 -.48). Since inflammatory triggers caninduce elevated BAFF production by dendritic cells, we assessed
plasma levels of cytokines indicative of an inflammatory process.
In 34 patients, the plasma levels of IP-10 and sTNFRII correlated
positively with BAFF levels (r51.627 and r51.642, respectively),
consistent with active inflammatory processes in thoseCGVHDpa-
tients with elevated BAFF levels. In a multi-step regression model,
the levels of circulating B cells, plasma IP-10 and sTNFRII com-
bined to strongly predict BAFF levels (R 5 .834). These findings
suggest that both homeostatic recovery of B cell populations con-
suming BAFF and inflammatory cytokine cascades initiated by do-
nor-anti-host reactivity combine to regulate BAFF levels post
transplant.347
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Introduction: Acute Graft-versus-host disease (aGVHD) is
a major complication of allogeneic stem cell transplantation (al-
loSCT). Risk factors include patient age, sex matching, CMV status
and degree of match. Regulatory T cells are critical for immune tol-
erance processes such as aGVHD, and express the transcription fac-
tor FOXP3, a member of the forkhead/winged-helix family,
identified as a key regulatory gene required for the development
and activity of these cells. It has been suggested that genetic expres-
sion of FOXP3 is inversely correlated with the severity of the
GVHD. We studied donors DNA looking for 5 polymorphisms
on the promoter region of the FOXP3 gene, and we tried to corre-
late them with presence and degree of aGVHD. Patients and
Methods: We studied donors of stem cells for allogeneic stem
cell transplants. We looked for the presence of the following poly-
morphisms by PCR: POL01–5906 T/A rs2869211; POL03–3279
A/C rs3761548; POL04–2383 C/T rs3761549; POL05–1383 C/T
rs2232364; POL06–924 A/G rs2232365.Results:Our sample con-
sisted of 31 donors, all siblings. In them we found only 2 of the 5
FOXP3 polymorphisms, either as homozygous or heterozygous.
These polymorphisms were found in 15/31 donors, with 12 being
homozygous (38.7%), and 3 heterozygous (9.7%). These genes
polymorphisms were POL03 y POL06. The most observed poly-
morphism was POL-06 with 9 cases, while POL-03 was found in
6 donors. Only sex difference and CMV status had an elevated haz-
ard ratio for developing GVHD (HR5 1.18, CI95%: 0.18 to 7.64;
p 5 0.85) and (HR 5 3.0, CI95%: 0.07 to 126; p 5 0.46) respec-
tively. We found no statistically significant difference in the inci-
dence of GVHD between patients who had received cells from
donor with or without a FOXP3 polymorphism (p 5 0.87). When
we analyzed the risk of presenting GVHD, results suggest that hav-
ing one of the 2 positive polymorphisms of the FOXP3 gene could
have a protective effect for the patient. For POL03 HR 5 0.87,
CI95%:0.18 to 4.14; p 5 0.86, and for POL06, HR 5 1, CI95%:
0.37 to 2.64, p5 0.67.Conclusions:Even though our sample is still
small to make conclusive remarks, we believe that our results point
toward some level of protection from acute GVHD in patients re-
ceiving cells from donors expressing POL03 and POL06. It is
also worthwhile mentioning the relatively high frequency of these
polymorphisms, as well as the absence of the other 3.348
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